Abstract 188P
Background
Survival and prognosis data in cholangiocarcinoma patients in routine clinical practice has been limited. This study aimed to determine the survival of cholangiocarcinoma patients and to investigate prognostic factors for survival in cholangiocarcinoma patients.
Methods
This cohort study retrospectively reviewed 158 records of cholangiocarcinoma patients treated in Oncology Unit, Department of Medicine, Rajavithi hospital from 1 January 2004 to 31 December 2017. Clinical characteristics, treatments, and outcomes were collected and analyzed.
Results
There were 158 patients whose median age was 58 years old while 69.6% of those had a good performance status (ECOG PS) of 0-1. The median survival time for all was 9.5 months (95% CI = 7.3-11.6) and the 1-year survival rate was 37.3%. After curative surgery (n = 49), 35 patients (71.4%) had tumor recurrence with the median disease-free survival of 8.81 months (95% CI = 6.93-10.68). Patients who received first-line palliative chemotherapy (n = 68) had the median progression-free survival of 4.3 months (95% CI = 3.51-5.10). The overall response rate to first-line chemotherapy was 7.3%. Variables analyzed by univariate analysis including ECOG PS of 3-4 (p < 0.001), neutrophil/lymphocyte ratio >/= 4 (p 0.004), intrahepatic cholangiocarcinoma (compared with hilar cholangiocarcinoma, p 0.005), distant metastasis in all sites (p < 0.001) and TNM stage IV disease (p < 0.001) were significant factors for shorter survival time. While surgical treatment, adjuvant chemotherapy and radiation, and palliative chemotherapy were significantly associated with better survival (p < 0.001). Multivariate analysis identified ECOG PS of 3-4 (p 0.001), intrahepatic type (p 0.001) and TNM stage IV disease (p 0.033) as independent poor prognostic factors for survival. Furthermore, receiving surgery and palliative chemotherapy administration (p < 0.001) were independent significant predictors associated with better survival compared to best supportive care alone.
Conclusions
Poor ECOG performance status of 3, intrahepatic cholangiocarcinoma type and TNM stage IV disease were adverse prognostic factors whereas surgical treatment and palliative chemotherapy had a crucial role in treatment for cholangiocarcinoma patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Oncology unit, Internal Medicine Department, Rajavithi Hospital.
Funding
Rajavithi Hospital.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract